Codi QR

Type 2 asthma paediatric patients eligible for dupilumab: An Italian biomarker-based analysis

Background: Type 2 inflammation is the principal determinant of asthma in children, and it leads to the downstream activation of eosinophils (EOS), the production of immunoglobulin-E (IgE), and increased levels of fraction of exhaled nitric oxide (FeNO). Dupilumab received the approval for the treat...

Descripció completa

Guardat en:
Autors principals: Giorgio Piacentini, MD, Alessandro Fiocchi, MD, Gianluigi Marseglia, MD, Michele Miraglia Del Giudice, MD, Renato Cutrera, MD, Rossella Bitonti, MSc, Francesca Fanelli, MSc, Annalisa Stassaldi, MSc, Giuliana Nicolosi, MD, Gianluca Furneri, MSc
Format: Artigo
Idioma:Inglês
Publicat: Elsevier 2024-08-01
Col·lecció:World Allergy Organization Journal
Matèries:
Type 2 asthma
Dupilumab
Biomarker
Italy
Accés en línia:http://www.sciencedirect.com/science/article/pii/S1939455124000644
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars